Business
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
PARAMUS, NJ, March 12, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel,
About this update from Polaryx Therapeutics, Inc.
[{"type":"text","content":"PARAMUS, NJ, March 12, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces its participation in two upcoming events supporting the Krabbe disease community. These events reflect Polaryx’s ongoing commitment to advancing research and strengthening engagement with patients, caregivers, and clinicians. 2026 Krabbe Translational Research Network Members of the Polaryx executive team, including Dr. Lisa Bollinger, Chief Medical Officer, Dr. Shrijay Vijayan, Chief Scientific and Business Development Officer, and Dr. Minsu Kang, Director of Regulatory and Clinical Affairs, will attend the 2026 Krabbe Translational Research Network (KTRN) meeting taking place March 18-20, 2026 in Minneapolis, Minn. Presented by the Rosenau Family Research Foundation, the KTRN meeting is dedicated to accelerating Krabbe research and engages in focused, data‑driven working sessions that integrate emerging insights across GALC biology, large‑animal and cellular models, newborn‑screening interpretation, and therapeutic development. The KTRN functions as a collaborative scientific forum designed to facilitate the exchange of mechanistic, preclinical, and early clinical evidence that may inform future research and clinical development strategies for Krabbe disease. “Polaryx deeply values these opportunities to remain closely aligned with emerging scientific insights while engaging directly with treating clinicians, caregivers and patient advocates to understand the evolving landscape of the disease,” said Dr. Bollinger. 2026 Putt-Putt to #CureKrabbe The Polaryx team will also be attending the 2026 Putt-Putt to #CureKrabbe on March 20, 2026 in Edina, Minn. The event will be hosted by KrabbeConnect, a patient organization recognized by the National Organization of Rare Diseases (NORD) and dedicated to raising awareness and strengthening engagement with the Krabbe community. Polaryx continues to pursue its mission of addressing significant unmet medical needs in rare pediatric disorders by advancing the launch of SOTERIA, its phase 2, open-label, single-arm trial designed to evaluate the safety, tolerability, and clinical activity of Polaryx’s lead candidate, PLX-200. The trial will evaluate PLX-...